Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate Update September 27, 2022 • 8:15 AM EDT
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting September 8, 2022 • 7:00 AM EDT
Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer August 9, 2022 • 9:00 AM EDT
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital August 3, 2022 • 8:30 AM EDT
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference June 21, 2022 • 8:00 AM EDT
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed Glioblastoma June 15, 2022 • 9:00 AM EDT
Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference June 10, 2022 • 9:00 AM EDT
Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement June 3, 2022 • 9:00 AM EDT
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for Glioblastoma May 27, 2022 • 9:30 AM EDT
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate Update May 13, 2022 • 8:00 AM EDT